XBiotech

211 posts / 0 new
Letzter Beitrag
Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

XBiotech to Deliver Presentation on Novel Study Design and Phase III Results From European Study on Xilonix(TM) During Meeting at the European Parliament

AUSTIN, Texas, March 02, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), developer of True Human(TM) therapeutic antibodies, announced today that its Medical Director Michael Stecher, M.D., will be included in a delegation assembled by EuropaColon to present the latest colorectal cancer research and advocacy-related perspective in a meeting at the European Parliament hosted by MEP Dr Alfred Sant.

EuropaColon is a patient advocacy group that aims to unite patients, caregivers, healthcare professionals, politicians, the media and the public in the fight against colorectal cancer. The meeting at the European Parliament will launch European Colorectal Cancer Awareness Month, an annual initiative held in March now in its ninth prestigious year.

#ECCAM16 aims to raise awareness of colorectal cancer across Europe about the critical importance of screening and to reduce deaths through early diagnosis with increased knowledge and better understanding of how the disease can be prevented and treated.

Dr. Stecher's presentation will cover the results of the recently completed Phase III European study for Xilonix(TM), a True Human(TM) monoclonal (IgG1k) antibody, in the treatment of advanced, symptomatic colorectal cancer. In addition, Dr. Stecher will highlight the novel design of the study endpoints which were developed in conjunction with the European Medicines Agency.

Jola Gore-Booth, Founder and CEO of EuropaColon, commented, "Colorectal cancer is treatable and potentially curable when diagnosed early, making formal population screening programs key in the fight against this disease. It also is critical that patients have access to the latest treatment options, particularly for those with advanced disease who are suffering from symptoms that preclude treatment with currently approved therapies. I am delighted to be able to feature information on an innovative phase III study design at this meeting."

Dr. Stecher added, "It is important to participate in multidisciplinary efforts to improve colorectal cancer care at all stages, from screening to late-line therapy. As we prepare to submit our Marketing Authorization Application to the European Medicines Agency for Xilonix(TM) in the treatment of advanced colorectal cancer, we're excited to participate in this meeting."

Every year approximately 470,000 people are diagnosed with colorectal cancer in Europe and half this number will not survive.1 Colorectal cancer is currently the second leading cause of cancer death in Europe2, and the incidence of colorectal cancer is expected to rise 12 percent by 20203. However, a number of European countries still do not have formal population screening programs for colorectal cancer.

About European Colorectal Cancer Awareness Month

Launched in 2008 at the European Parliament in Brussels by EuropaColon, European Colorectal Awareness Month (ECCAM) is an annual awareness-raising initiative held in March; coordinated at European level by the organization and by its Member Groups at national level.

Predominantly organized by EuropaColon's Member Groups, many events have taken place throughout Europe over the years. The political momentum generated by ECCAM also serves as an important advocacy tool and it has notably contributed to the advancement of National Cancer Plans and policies in a number of European countries.

#ECCAM16 aims to raise the profile and awareness of Colorectal Cancer (also known as Bowel Cancer) across Europe and the critical importance of screening; to reduce deaths through increased knowledge of the risks and better understanding of how the disease can be prevented.

http://investors.xbiotech.com/phoenix.zhtml?c=253990&p=irol-newsArticle&...

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

Toll, dass sich solche interessensgruppen für neue und moderne behandlungsmöglichkeiten einsetzen. Ich glaube immer mehr, dass die antikörper funktionieren. Wäre wohl echt der jackpot, sind ja enorme zahlen, alleine im darmkrebsbereich. 

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

European Medicines Agency Grants Eligibility for Submission of XBiotech’s Marketing Authorization Application (MAA)

 

AUSTIN, Texas, March 04, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (XBIT) announced today that the Company has been granted eligibility by the European Medicines Agency (EMA) to submit a Marketing Authorization Application (MAA) for its candidate therapy Xilonix™ for the treatment of advanced colorectal cancer. An MAA contains all relevant clinical, scientific and manufacturing information that describes how a drug works and is manufactured. The MAA is submitted as the first step in the process of seeking approval to sell the drug in the European Union member nations. XBiotech was granted the ability to submit its MAA through the Centralised Procedure and has been assigned Rapporteurs, the highly specialized project managers that will shepherd the MAA through the review process. The Company expects to submit an MAA shortly.

John Simard, CEO of XBiotech, stated, "We are gratified that our marketing application has been granted eligibility by the European Medicines Agency. We are looking forward to the submission and review process.”

In a recently concluded Phase III study in the EU, patients treated with the antibody therapy Xilonix had failed all conventional therapies and had inoperable or metastatic disease. Patients were also required to have multiple symptoms of disease—each of which correlated with poor prognosis. Treatment of these advanced colorectal cancer patients indicated that the Xilonix antibody therapy was able to control tumour-related symptoms associated with morbidity and death. Furthermore, the Phase III study indicated that Xilonix therapy appears to lack the frank toxicity of many other anti-cancer agents, and that the therapy may not cause the negative hematological effects that result in immunosuppression, eliminating a troubling toxicity and life-threatening risk factor of other anti-cancer therapies used to treat advanced disease.

In the advanced cancer patients treated in this recently completed Phase III study for Xilonix, there was a 76% relative improvement in response rate in patients treated with the antibody, as compared to placebo (p=0.0045). Secondary endpoints used in the Phase III study—control of thrombocytosis and systemic inflammation—which are known prognosticators of overall survival, were also significantly improved in the treated patients compared to controls (respectively p=0.003, p=0.004). In addition to these planned analyses, the study revealed a higher incidence of stable disease in the antibody-treated patients, and there were fewer significant adverse events (SAEs) in the treatment arm than in the placebo group.

The Company believes that the recent and earlier clinical findings to be presented in its MAA provide a compelling case for the clinical benefit of the antibody therapy and establish Xilonix as a groundbreaking therapy for advanced colorectal cancer.

Few agents are reliably able to mediate durable responses in metastatic disease; and many agents have significant trade-offs in terms of side effects, such that the overall benefit of therapy may be questionable in patients with advanced cancer. Based on novel objective response (OR) criteria, developed by XBiotech in conjunction with the EMA’s Scientific Advice Working Group, XBiotech’s Xilonix was evaluated for its ability to control disease-related symptoms that inversely correlate with survival. The Company believes that using this symptom-based objective response criteria will allow better assessment of overall benefit from therapy in advanced cancer patients.

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

XBiotech Announces Submission of Marketing Authorization Application (MAA) for Candidate Colorectal Cancer Therapy to European Medicines Agency (EMA)

AUSTIN, Texas, March 08, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the Company has now submitted its Marketing Authorization Application (MAA) for its candidate therapy (Xilonix™) for advanced colorectal cancer to the European Medicines Agency (EMA). Submission of the MAA for Xilonix is necessary for the Company to gain approval to sell the drug in European Union member nations. The Company, which only recently was granted eligibility to submit its MAA through the Centralised Procedure, has made a remarkably quick turnaround for delivery of the extensive MAA documentation needed for the EMA review.

John Simard, CEO of XBiotech, commented, "With submission of the Marketing Authorization Application, we now look forward to the review process.”

Few agents are reliably able to mediate durable responses in metastatic disease. And many agents have significant trade-offs in terms of side effects. In patients with advanced disease, often weakened from successive rounds of cytotoxic therapy, the risk-benefit associated with further therapy is often questionable. Based on novel objective response (OR) criteria, developed by XBiotech in conjunction with the EMA’s Scientific Advice Working Group, the candidate therapy subject of the MAA was recently evaluated in a Phase III clinical study for the ability to control disease-related symptoms that inversely correlate with survival. The Company believes using the symptom-based objective response criteria will allow better assessment of overall benefit from therapy in advanced cancer patients.

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135
Neues rating

XBiotech Inc (NASDAQ:XBIT)‘s stock had its “buy” rating reiterated by equities researchers at Noble Financial in a report released on Tuesday, MarketBeat Ratingsreports. They currently have a $21.00 price objective on the biopharmaceutical company’s stock. Noble Financial’s price objective suggests a potential upside of 152.10% from the company’s previous close.

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Yetichris hat am 08.03.2016 - 16:08 folgendes geschrieben:

XBiotech Inc (NASDAQ:XBIT)‘s stock had its “buy” rating reiterated by equities researchers at Noble Financial in a report released on Tuesday, MarketBeat Ratingsreports. They currently have a $21.00 price objective on the biopharmaceutical company’s stock. Noble Financial’s price objective suggests a potential upside of 152.10% from the company’s previous close.

Danke, das ist das erste mir bekannte Rating für XBIT - $21.00 passt Smile

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540
Wieder News...

XBiotech Enrolls Final Patient in Phase I Portion of Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus

AUSTIN, Texas, March 09, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today completion of enrollment in the Phase I portion of the ongoing clinical study to evaluate its antibody treatment for Staphylococcus aureus (S. aureus) infections. The Company is developing a True Human™ antibody to treat serious, blood-borne infections caused by S. aureus including methicillin-resistant (MRSA) strains.

The Phase I portion involved dose escalation to establish a safe dose-level to use during the Phase II expansion. The Phase I portion of the study will not be complete until the last patient enrolled is found to be free of dose-related toxicities. The Phase II portion of the trial will then commence and include a larger cohort of patients that will be used to further investigate safety and efficacy of the therapy.

XBiotech’s novel antibody therapy, known as 514G3, was developed from a human donor with natural antibodies effective at neutralizing MRSA and non-MRSA forms of S. aureus. 514G3 knocks out the principle immune evasion mechanism of the bacteria, allowing white blood cells to detect and destroy the bacteria. 514G3 is expected to treat all strains of MRSA and can be used without consideration for strain-specific resistance to various antibiotics. As a True Human monoclonal antibody, 514G3 is expected to be well tolerated without the side effects or risks of antibiotics.

Michael Stecher, M.D., XBiotech’s Medical Director, said, “S. aureus is a major disease problem worldwide and we are encouraged by the advancement of 514G3 in the clinic. We are committed to develop this therapy as expeditiously as possible to address the growing unmet need worldwide for a treatment against these deadly infections.”

The randomized, placebo-controlled, Phase 1/2 study is designed to evaluate dosing, safety and efficacy of 514G3 and will enroll 52 patients at approximately 16 clinical sites in the United States, Europe and Southeast Asia. Hospitalized patients with S. aureus bacteremia will be randomized to receive 514G3 plus standard of care antibiotics or placebo plus antibiotics. For more information about the study, visit www.clinicaltrials.gov.

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

Xbit rules. Zumindest in den medien. Smile 

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Yetichris hat am 09.03.2016 - 14:42 folgendes geschrieben:

Xbit rules. Zumindest in den medien. Smile

Ja starker Newsflow von XBIT auch wenn es Kurstechnisch nichts bringt... Gut waren auch keine Knallernews Wink

 

Lowrey70
Bild des Benutzers Lowrey70
Offline
Zuletzt online: 27.09.2017
Mitglied seit: 24.02.2016
Kommentare: 26
Investieren

Hey Leute,
Biotechnologie ist ja generell interessant, vor allem für Investoren, da ständig neue Fortschritte gemacht werden. 

Hab gerade eine Liste gefunden, mit den fortgeschrittensten Biotechnologie Unternehmen, welche in der Krebsforschung aktiv sind. 

Könnte spannend sein, denn diese Firmen sind auf dem guten Weg echt grosse Durchbrüche zu machen. In sie zu investieren sollte man sich also überlegen.

 

http://labiotech.eu/infographic-the-top-8-deadliest-cancers-and-who-in-b...

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

Mir passt das eigentlich ganz gut. Habe vor 4 wochen mobileye gekauft, um die gunst der stunde des salons in genf zu nutzen. bald werd ich die umschichten auf xbit, da passt mir der kurs doch ganz gut...:-)

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

was hältst von der transaktion zwischen simard und thorpe mckenzie?

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Yetichris hat am 22.03.2016 - 23:34 folgendes geschrieben:

was hältst von der transaktion zwischen simard und thorpe mckenzie?

Meinst Du die Meldungen von gestern Abend?

http://investors.xbiotech.com/phoenix.zhtml?c=253990&p=IROL-sec

Hmn das kann viele Gründe haben... Simard hält ja mehr als 6 Mio Aktien, mir ist lieber er verkauft warum auch immer einen Teil davon an W. Thorpe McKenzie welcher mit 4 Mio Aktien auch satt XBIT hält als über den Markt...

Womöglich passen Sie die Anteile an oder es ist Teil eines Deals, keine Ahnung.

Was denkst Du?

 

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Auf alle Fälle Spannend, in einer Woche gibt es die Zahlen bzw. ein Update:

XBiotech to Provide Fourth Quarter and Full Year 2015 Business update

AUSTIN, Texas, March 22, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today it will host a conference call and live audio webcast on Wednesday, March 30, 2016, at 8:30 a.m. Eastern Time, to provide an overview of its corporate and clinical activities.  The call will encompass developments during the fourth quarter and year ended December 31, 2015.

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

Ich schätze es auch eher als positiv ein. kann es irgendwie nicht so recht einschätzen. aber anscheinend glaubt mckenzie fest an xbit. Halt ein bitterer nachgeschmack, dass sich simard so kurz vor den zahlen von den aktien trennt. 

Vor dem jahresbericht grauts mir ein bisschen... Auf die updates bin ich aber gespannt, obwohl ich nach dem newsflow der letzten wochen nicht so viel neues erwarte. Aber lassen wir uns überraschen.

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Yetichris hat am 23.03.2016 - 10:52 folgendes geschrieben:

Ich schätze es auch eher als positiv ein. kann es irgendwie nicht so recht einschätzen. aber anscheinend glaubt mckenzie fest an xbit. Halt ein bitterer nachgeschmack, dass sich simard so kurz vor den zahlen von den aktien trennt. 

Vor dem jahresbericht grauts mir ein bisschen... Auf die updates bin ich aber gespannt, obwohl ich nach dem newsflow der letzten wochen nicht so viel neues erwarte. Aber lassen wir uns überraschen.

Die Zahlen werden Biotech like kein grosser Event sein, wichtig halt wie viel Geld Sie noch haben und wie viel Sie jährlich verbrennen... Spannender eher die die Updates der Pipeline sofern es was neues gibt, vor allem zu Xilonix.

Sehe es weniger problematisch wegen der Transaktion vor den Zahlen... Die beiden Herren müssten eigentlich den selben Wissensstand haben.

Hast Du schon mal folgendes Video gesehen?
https://www.youtube.com/watch?v=5_NVm2vv4tE

Marketing like gut gemacht Wink Sie Herren Simard, Vasella und Mackenzie Thorpe erzählen über XBIT.

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

Top video, habe ich bisher noch nicht gesehen, danke! Das chaos hinter simard; kein wunder hats bei p3 verwechslungen gegeben! Smile wusste nicht, das mckenzie so nah an xbit dran ist. Dann gefällt mir die transaktion schon viel besser.

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540
Wieder News!

XBiotech Announces European Medicines Agency (EMA) Validates Marketing Authorization Application (MAA) for Xilonix™ in the Treatment of Advanced Colorectal Cancer

AUSTIN, Texas, March 23, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the Company’s Marketing Authorization Application (MAA) for Xilonix™, which is intended for the treatment of advanced colorectal cancer, has been validated by the European Medicines Agency (EMA).  With this validation, the application process is complete and the EMA’s Committee for Medicinal Products for Human Use (CHMP) will now begin the assessment of Xilonix through the centralized review procedure. If approved through this procedure, Xilonix will be licensed in all EU member states.

“The MAA for Xilonix is based on a recently completed Phase III double-blind, placebo-controlled clinical study where the antibody therapy met its primary and secondary endpoints in advanced colorectal cancer,” said John Simard, CEO of XBiotech. "The acceptance of our application for review by the EMA is a significant milestone in our oncology program and leads us one step closer towards potentially addressing a serious and growing unmet medical need for patients suffering from advanced colorectal cancer in the European Union. We look forward to continuing to work with the EMA during the review process.”

The incidence of advanced, symptomatic colorectal cancer is growing globally with economic development and aging demographics. Persons with advanced colorectal cancer are frequently weakened from successive rounds of cytotoxic therapy, and the risk-benefit associated with further therapy is often questionable. Objective response criteria were developed by XBiotech in collaboration with the EMA’s Scientific Advice Working Group and used to establish clinical benefit in a Phase III study of Xilonix. Findings showed a significant improvement in overall response rate for Xilonix-treated patients versus placebo. The objective response criteria consisted of controlling key symptoms (pain, fatigue, appetite loss, and muscle loss) associated with disease progression and prognosis for overall survival. The Company believes that these criteria will allow excellent assessment of overall clinical benefit from therapy in advanced cancer patients.

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Yetichris hat am 23.03.2016 - 12:55 folgendes geschrieben:

Top video, habe ich bisher noch nicht gesehen, danke! Das chaos hinter simard; kein wunder hats bei p3 verwechslungen gegeben! Smile wusste nicht, das mckenzie so nah an xbit dran ist. Dann gefällt mir die transaktion schon viel besser.

Ja Chaos Wacko

Mackenzie Thorpe ist neben Simard der grösste Aktionär und nebenbei Director. Der hat den Finance Hintergrund und Simard und Vasella bringen das Pharmawissen und womögliche Kontakte.

Mal schauen wie es weiter geht... Denke XBIT haben viele noch nicht auf dem Radar... Sollten die liefern dann sind Kurse unter USD 10.00 definitv Geschichte.

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Apro Chaos... Die gestrige Meldung der EMA ist nach dem anfänglichen PIII Chaos der Xilonix Daten sehr positiv aufzufassen.

Dem entsprechend hat XBIT gestern gegen den sackschwachen NBI (-3.4%) mit einem netten Plus von gegen 5%
stark geschlossen.

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

Wow, tolle performance. Und heute schon 2-stellig. Hoffentlich hats adam f. nicht gesehen. Ich folge dem seit dem ersten post gegen xbit auf twitter. Ahnung hat er zumindest.

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Yetichris hat am 24.03.2016 - 16:17 folgendes geschrieben:

Wow, tolle performance. Und heute schon 2-stellig. Hoffentlich hats adam f. nicht gesehen. Ich folge dem seit dem ersten post gegen xbit auf twitter. Ahnung hat er zumindest.

Ja XBIT war letzten Donnerstag stark, die NEWS vom 23.03 (XBiotech Announces European Medicines Agency (EMA) Validates Marketing Authorization Application (MAA) for Xilonix™ in the Treatment of Advanced Colorectal Cancer) haben ich denke durchgedrückt und für Fantasie gesorgt.

Gestern wieder News…
XBiotech Advances to Phase II Portion of Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus
http://www.xbiotech.com/about/news/xbiotech-advances-to-phase-2-portion-of-clinical-study-of-novel-true-human-therapeutic-antibody.html

Anfänglich der Kurs deutlich abgesackt aber am Ende wieder über USD 10.00 knapp im Minus wie der US Biotech Sektor geschlossen… Morgen Zahlen / Update Smile

 

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

Die spannung steigt. Noch 1h. Meine nervosität ist heute, nach den zahlen von evolva und dem darauf folgendem kurssturz, ziemlich hoch. Klar, ist eine komplett andere situation mit der saftigen enttäuschung mit eversweet. Aber trotzdem. Hoffentlich kommen keine unerwarteten abschreiber, bezüglich der verpatzen p3 studie oder irgendwelche kosten auf xbit zu. Ansonsten dürfte ja alles bekannt sein... 

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Yetichris hat am 30.03.2016 - 13:26 folgendes geschrieben:

Die spannung steigt. Noch 1h. Meine nervosität ist heute, nach den zahlen von evolva und dem darauf folgendem kurssturz, ziemlich hoch. Klar, ist eine komplett andere situation mit der saftigen enttäuschung mit eversweet. Aber trotzdem. Hoffentlich kommen keine unerwarteten abschreiber, bezüglich der verpatzen p3 studie oder irgendwelche kosten auf xbit zu. Ansonsten dürfte ja alles bekannt sein... 

Ruhig Blut, eine neue Ausrichtung wie bei EVE wird es bei XBIT kaum geben. Denke die Zahlen und dass Update werden Formsache sein. Vergiss nicht, dass Director W. Thorpe McKenzie satt XBIT gekauft hat vor wenigen Tagen.

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

Pre market sieht mal super aus!

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Yetichris hat am 30.03.2016 - 15:19 folgendes geschrieben:

Pre market sieht mal super aus!

Ja aber nur mit kleinem Vol.

http://www.nasdaq.com/de/symbol/xbit/premarket

Die Zahlen wurden vermutlich im CC erwähnt, ein "Press Release" habe ich aber noch nicht gesehen / bekommen...

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540
Äusserst Positiv zu werten

European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix(TM), XBiotech's True Human(TM) Therapeutic Antibody Treatment for Advanced Colorectal Cancer

(GLOBE NEWSWIRE via COMTEX) --- Xilonix poised to be a first-in-class, True Human monoclonal (IgG1k) antibody

- First to neutralize biological activity of interleukin-1a (IL-1a), developed specifically to treat advanced cancer

- EMA decision could speed access to Xilonix for EU patients

AUSTIN, Texas, April 04, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated review for Marketing Authorization of Xilonix, the Company's first-in-class True Human monoclonal (IgG1k) antibody treatment for advanced colorectal cancer. The CHMP grants accelerated review for medicines deemed to be of public health importance and that represent therapeutic innovation. The accelerated review procedure allows the CHMP to grant an opinion two months earlier than the normal 210-day procedure. With this action, a decision on Xilonix's approval could come as early as third quarter 2016.

Xilonix is XBiotech's lead True Human therapeutic antibody and a potential breakthrough for patients with advanced colorectal cancer. Xilonix specifically targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis (the growth and spread of tumors), as well as mediate symptoms such as metabolic dysregulation (e.g., loss of weight and muscle mass), fatigue and anxiety associated with advanced cancer. 

XBiotech recently received validation of its Marketing Authorization Application (MAA) for Xilonix based on results of a Phase III study, which showed a 76% relative improvement in response rate in patients treated with the antibody, as compared to placebo (p=0.0045). Patients treated in the Phase III study had colorectal tumors that were metastatic or inoperable, had failed all recommended forms of chemotherapy and most other forms of therapy, and suffered from symptoms including pain, fatigue, anorexia and wasting. The patients treated in the Phase III study were considered to represent a large patient population that is physically and emotionally exhausted from the disease and treatment-related toxicities.

"XBiotech is encouraged by CHMP's action to grant accelerated review of Xilonix," said John Simard, Chairman, Chief Executive and founder of XBiotech. "There is an urgency to provide advanced colorectal cancer patients with access to new treatments that have been developed with their specific needs in mind."

In the U.S., Xilonix has received Fast Track designation by the Food and Drug Administration (FDA) for the treatment of advanced colorectal cancer. 

http://investors.xbiotech.com/phoenix.zhtml?c=253990&p=irol-newsArticle&...

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Endlich mal werden News von XBIT auch mal positiv angenommen / aufgenommen:

XBIT $10.50 (+1.04 /10.99%)

Yetichris
Bild des Benutzers Yetichris
Offline
Zuletzt online: 19.12.2018
Mitglied seit: 23.07.2015
Kommentare: 135

XBiotech Inc (NASDAQ:XBIT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Analyst Ratings Network.com reports. The brokerage currently has a $11.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 10.00% from the company’s previous close.

Aurum
Bild des Benutzers Aurum
Offline
Zuletzt online: 17.01.2020
Mitglied seit: 03.09.2008
Kommentare: 2'540

Yetichris hat am 05.04.2016 - 20:08 folgendes geschrieben:

XBiotech Inc (NASDAQ:XBIT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Analyst Ratings Network.com reports. The brokerage currently has a $11.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 10.00% from the company’s previous close.

Grundsätzlich kannste Zacks "rauchen" auch wenn diesmal Ihr Kursziel gestern bereits erreicht worden ist Wink

Achtung XBIT ist nun bei RSI 70 = Überkauft... Sollten keine News kommen ist kurzfristig die Chance eines Rücksetzers grösser als ein weiterer Anstieg.

Seiten